Spectrum Pharmaceuticals Inc. (SPPI) announced Tuesday that the interim data from its Phase 2 clinical study of poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer was presented in Yokohama, Japan.
from RTT - Before the Bell http://ift.tt/2hOPWbW
via IFTTT
No comments:
Post a Comment